Renflexis is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Organon Llc. The primary component is Infliximab.
Product ID | 78206-162_488396cb-243a-45bf-b936-fcde5dcdb465 |
NDC | 78206-162 |
Product Type | Human Prescription Drug |
Proprietary Name | Renflexis |
Generic Name | Infliximab |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2017-04-21 |
Marketing Category | BLA / |
Application Number | BLA761054 |
Labeler Name | Organon LLC |
Substance Name | INFLIXIMAB |
Active Ingredient Strength | 100 mg/1 |
Pharm Classes | Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-06-01 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0006-4305 | Renflexis | infliximab |
78206-162 | Renflexis | infliximab |
57894-160 | INFLIXIMAB | INFLIXIMAB |
57894-030 | REMICADE | INFLIXIMAB |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RENFLEXIS 87480588 5542207 Live/Registered |
Merck Sharp & Dohme Corp. 2017-06-08 |
RENFLEXIS 86307793 5311653 Live/Registered |
Merck Sharp & Dohme Corp. 2014-06-12 |